Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort.

ABSTRACT:

Background

Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to treatment completion. Evaluate safety of longer MDR/RR-TB regimens containing bedaquiline and/or delamanid.

Methods

Multicentre (16 countries), prospective, observational study reporting incidence and frequency of clinically relevant adverse events of special interest (AESIs) among patients who received MDR/RR-TB treatment containing bedaquiline and/or delamanid. The AESIs were defined a priori as important events caused by bedaquiline, delamanid, linezolid, injectables, and other commonly used drugs. Occurrence of these events was also reported by exposure to the likely causative agent.

Results

Among 2296 patients, the most common clinically relevant AESIs were perip

SUBMITTER: Hewison C 

PROVIDER: S-EPMC9522425 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature